Daiichi Sankyo: Atrial Fibrillation trials

The registry lists 22 Atrial Fibrillation studies with Daiichi Sankyo as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 2 3Phase 3 7No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)CompletedNCT02943785Phase 3Results posted
• Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter AblationCompletedNCT02942576Phase 3Results posted
• Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary InterventionCompletedNCT02866175Phase 3Results posted
• Study of DU-176b Aged 80 Years or OlderCompletedNCT02801669Phase 3Results posted
• Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)CompletedNCT02072434Phase 3Results posted
• Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal ImpairmentCompletedNCT01857622Phase 3Results posted
• Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial FibrillationCompletedNCT00829933Phase 2Results posted
• DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial FibrillationCompletedNCT00806624Phase 2Results posted
• Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial FibrillationCompletedNCT00781391Phase 3Results posted
• A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial FibrillationCompletedNCT00504556Phase 2Results posted
• A Real World Evidence Retrospective Data Collection Study of Edoxaban and RivaroxabanCompletedNCT07874555
• A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial FibrillationCompletedNCT05804747
• Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial FibrillationCompletedNCT05262322
• Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in ChinaCompletedNCT04747496
• Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in TurkeyCompletedNCT04594915
• Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary InterventionCompletedNCT04519944
• Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)CompletedNCT03247582
• Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)CompletedNCT03247569
• Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical OutcomesCompletedNCT02964949Not applicable
• Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)CompletedNCT02951039
• Edoxaban Management in Diagnostic and Therapeutic ProceduresCompletedNCT02950168
• Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial FibrillationCompletedNCT02944019